Tesamorelin Trims Waistlines in HIV Patients But Falls Short on Brain Benefits
A phase 2 trial finds tesamorelin reduces abdominal obesity in virally suppressed HIV patients but shows no significant cognitive improvement.
Summary
Researchers tested whether tesamorelin, a growth hormone-releasing hormone analog, could improve neurocognitive impairment in virally suppressed HIV patients with abdominal obesity. Over 6 months, 73 participants were randomized to tesamorelin or standard of care. While tesamorelin meaningfully reduced waist circumference by a median of 2.7 cm and raised IGF-1 levels, it did not produce a statistically significant improvement in cognitive performance compared to standard care. The tesamorelin group showed a trend toward cognitive improvement, but the between-group difference was non-significant. The study was limited by small sample size and lack of a placebo arm, leaving open whether longer treatment or larger trials might reveal cognitive benefits from sustained abdominal fat reduction in this population.
Detailed Summary
People living with HIV who achieve viral suppression through antiretroviral therapy still face elevated risks of neurocognitive impairment. One underexplored contributor is abdominal obesity, which is disproportionately common in this population and linked to visceral fat accumulation, systemic inflammation, and reduced levels of insulin-like growth factor 1 (IGF-1) — all of which may harm brain health. Tesamorelin, a synthetic growth hormone-releasing hormone, is already FDA-approved to reduce visceral fat in HIV patients, making it a logical candidate to test for cognitive benefits.
This 6-month phase 2 randomized open-label trial enrolled 73 virally suppressed, abdominally obese HIV-positive adults, assigning them 3:2 to either daily subcutaneous tesamorelin (2 mg) or standard of care. The primary outcome was change in neurocognitive performance at 6 months, with secondary outcomes including waist circumference, mood, and daily functioning.
Tesamorelin successfully reduced waist circumference by a median of 2.7 cm more than standard care (P=.015) and increased IGF-1 levels as expected. On the cognitive front, the tesamorelin group showed a trend toward improvement (mean change 0.146, P=.060), while the standard care group did not improve significantly. However, the between-group difference was not statistically significant (P=.673), meaning the trial failed to demonstrate a clear cognitive benefit from the intervention.
Notably, changes in IGF-1 did not correlate with cognitive scores or waist circumference changes, suggesting that IGF-1 elevation alone may not drive cognitive recovery even when fat loss is achieved.
The findings highlight that short-term abdominal fat reduction may not be sufficient to reverse established neurocognitive impairment in HIV. Longer intervention periods, placebo-controlled designs, and larger cohorts will be needed to determine whether tesamorelin or similar agents offer meaningful brain benefits in this vulnerable group.
Key Findings
- Tesamorelin reduced waist circumference by a median 2.7 cm more than standard care over 6 months (P=.015).
- No statistically significant difference in neurocognitive performance was found between tesamorelin and standard care groups (P=.673).
- Tesamorelin group showed a non-significant trend toward cognitive improvement (mean change 0.146, P=.060).
- IGF-1 levels increased with tesamorelin but did not correlate with cognitive outcomes or waist circumference changes.
- Study was underpowered and lacked a placebo arm, limiting conclusions about cognitive efficacy.
Methodology
Phase 2 randomized open-label trial with 73 participants assigned 3:2 to tesamorelin or standard of care over 6 months. Primary endpoint was change in neurocognitive performance; secondary endpoints included waist circumference, mood, and daily functioning. No placebo arm was included.
Study Limitations
The trial was underpowered with only 73 participants, limiting the ability to detect modest cognitive effects. The open-label design without a placebo arm introduces potential bias in subjective outcome measures. A 6-month duration may be insufficient to observe meaningful neurological changes from fat reduction.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.